ANDA 220046, held by Bpi Labs. Fluorescein Sodium.
As of Nov 16, 2026, ANDA 220046 (Fluorescein Sodium), held by Bpi Labs, was first approved by FDA on Apr 30, 2026, with 0 approved supplements and 0 published complete response letters.
Fluorescein Injection 10% (100 mg/mL) is indicated in diagnostic fluorescein angiography or angioscopy of the retina and iris vasculature.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 30, 2026 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Fluorescein SodiumEQ 500MG BASE/5ML (EQ 100MG BASE/ML) · injectable;intravenous | Fluorescein Sodium | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters